1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Phase III Data In Suspected NASH Boost Madrigal’s Profile, But Bigger Data To Come

 
• By Joseph Haas

Resmetirom, Madrigal’s THRβ agonist, demonstrates safety and tolerability, and succeeds on secondary efficacy endpoints in a study serving as a precursor to the firm’s pivotal Phase III trial.

Madrigal office
Madrigal unveils additional data de-risking NASH candidate resmetirom • Source: Madrigal

Madrigal Pharmaceuticals, Inc. continued the process of de-risking Phase III non-alcoholic steatohepatitis (NASH) candidate resmetirom on 31 January, releasing positive top-line data from the Phase III MAESTRO-NAFLD-1 study in suspected NASH patients, a precursor to the biopsy-driven pivotal Phase III MAESTRO-NASH study, which is expected to report data in the third quarter of 2022.

The MAESTRO-NAFLD-1 results showed the drug’s safety and tolerability and suggested hepatic fat-reducing and LDL

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Boehringer’s Next Generation IPF Drug Underwhelms

 
• By Andrew McConaghie

The company hoped its follow-up to blockbuster Ofev could clearly improve efficacy and safety benefits, but the full Phase III results from nerandomilast’s FIBRONEER-IPF fall short of a slam dunk.

Affimed’s ASCO ‘Hail Mary’ As Survival Chances Slim

 
• By Kevin Grogan

The German biotech has been forced into insolvency and NASDAQ suspension.

In Brief: Essence Raises Ionis Tryngolza Hypertriglyceridemia Filing Hopes

 
• By Sushmita Panda

Tryngolza has met endpoints in a moderate hypertriglyceridemia trial. Positive results in severe disease in Q3 could allow for a filing for a broader patient population than its currently approved indication of familial chylomicronemia syndrome.

Apnimed’s AD109 Could Be A Wake-Up Call For Sleep Apnea Market

 
• By Joseph Haas

The first of two Phase III trials in obstructive sleep apnea showed Apnimed’s combination pill can offer a therapeutic alternative to entrenched CPAP devices.

More from R&D